Roche Holding AG (XTER:RHO) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:RHO Roche Holding AG XTER:RHO
81 GF Score
Price €360.40
GF Value €295.26
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XTER:RHO
81GF Score
Roche Holding AG XTER:RHO
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (XTER:RHO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €360.40 is trading 22.1% above its estimated GF Value™ of €295.26. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XTER:RHO:

  • Short Ratio:
  • GF Value™: €295.26 vs. price of €360.40 (22.1% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the XTER:RHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
81GF Score

Get the complete analysis for XTER:RHO

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€360.40
Price
€295.26
GF Value